BMS-986142 clinical trials
Also written BMS-986142.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses BMS-986142 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BMS-986142
- 5
Studies by the year they started
7 studies that test it; most in 2016 (5)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses BMS-986142 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid ArthritisCompletedPhase 2Bristol-Myers SquibbNCT02638948Written as BMS-986142How we know
- Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's SyndromeTerminatedPhase 2Bristol-Myers SquibbNCT02843659Written as BMS-986142How we know
- The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female SubjectsCompletedPhase 1Bristol-Myers SquibbNCT02832180Written as BMS-986142How we know
- Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male SubjectsCompletedPhase 1Bristol-Myers SquibbNCT02880670Written as BMS-986142How we know
- A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe SubstratesCompletedPhase 1Bristol-Myers SquibbNCT02762123Written as BMS-986142 200mgHow we know
- Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy PatientsCompletedPhase 1Bristol-Myers SquibbNCT02456844Written as Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142How we know
- Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy SubjectsCompletedPhase 1Bristol-Myers SquibbNCT02257151Written as BMS-986142How we know